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Hereditary non-polyposis colorectal cancer (HNPCC) is an autosomal dominantly 
inherited predisposition to a variety of epithelial malignancies most notable colorectal 
and endometrial cancer.  Unlike other genetic predispositions to colorectal cancer 
HNPCC does not present with a premalignant phenotype, which as such makes it 
difficult to predict when or if an affected person will present with disease. The genetic 
basis of HNPCC has been conclusively shown to be due to mutations in genes 
involved in DNA mismatch repair. Four DNA mismatch repair genes are associated 
with HNPCC; hMSH2, hMLH1, hMSH6 and PMS2, with the majority affecting 
hMLH1 and hMSH2.  
 
Aim 
Mutations in any of the DNA mismatch repair genes have not been shown to result in 
any obvious genotype/phenotype correlation such that it is not possible to predict with 
any accuracy the type or age of onset of disease in persons harbouring the same 
mutation within and between families.  The most likely explanation for disease 
variation in persons harbouring the same mutation is either a genetic modifier of 
disease risk, environmental insult or a combination of both. Several reports suggest 
that genetic modifiers of disease risk are capable of influencing the age of disease 
onset in HNPCC and it is likely that many of them have not yet been identified. 
Recently several genome-wide association studies have revealed a number of 
colorectal cancer susceptibility loci on chromosomes 10p14, 8q23.3, 8q24, 11q23 and 
18q21. These loci are of particular importance as they are associated with an 
increased risk of colorectal cancer and may therefore act as modifiers of disease risk 
in individuals diagnosed with HNPCC. 
 
Materials and methods 
373 Australian and 311 Polish HNPCC patients with a molecular diagnosis of 
HNPCC have been examined for nine polymorphisms in the five loci described above. 
All DNA samples were genotyped to determine the allele frequency in the nine 
polymorphisms investigated. A statistically evaluation of the exact nature of the effect 
on disease risk was assessed using the statistical software package SPSS Graduate 
Pack Version 12.0.   
 
Results 
The statistical analysis revealed a number of significant results indicating that there 
might be a correlation between the different polymorphisms and disease development. 
In this study, hMLH1 mutation carriers harbouring the variant genotype for 
polymorphism rs3802842 were associated to development of colorectal cancer (CRC) 
at an earlier age than hMLH1 carriers harbouring the heterozygous or wild type 
genotype. This suggests that the particular polymorphism might act as a modifier for 
disease development in hMLH1 mutation carriers. Interestingly, these findings have 









In this study, some of the polymorphisms investigated have been associated with an 
altered risk of disease in HNPCC patients. Still, to confirm a correlation between 
disease development and the presence of some polymorphisms, more HNPCC 
populations needs to be studied. This will provide more information to specifically 
assess the likelihood of disease risk in HNPCC and thereby providing better tools for 
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1 INTRODUCTION  
1.1 Hereditary Non-Polyposis Colorectal Cancer (HNPCC) 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC), also known as Lynch 
syndrome is an autosomal dominantly inherited cancer syndrome which is associated 
with inherited defects in the DNA mismatch repair (MMR) pathway [1-5]. It is 
characterized by early age of disease onset, neoplastic lesions, microsatellite 
instability and increased incidence of extra-colonic cancers such as carcinoma of the 
endometrium, ovary, stomach, small bowel, ureter and renal pelvis [6-8]. Of these 
cancers, endometrial cancer is the most common cancer after colorectal cancer [9]. 
Interestingly, females with MMR mutation have a greater chance of developing 
endometrial cancer than colorectal cancer [9, 10].  HNPCC is the most common form 
of hereditary colon cancer, accounting for approximately 2-8% of all colorectal 
cancers (CRC), depending on the population studied [4]. HNPCC is not characterized 
as a cancer but a syndrome that increases a person’s risk of developing cancer. A 
person with HNPCC might never develop cancer, but their risk of developing cancer 
is much higher than in the general population. Up until 2007 it was considered that 
4% of the CRC population would develop CRC as a result of harbouring mutations in 
DNA mismatch repair genes [11]. Furthermore, disease penetrance estimates 
suggested that approximately 80% of men and 40% of women with HNPCC would 
develop CRC [6, 12]. However, more recent analysis suggests that 45% of men will 
develop CRC and 15% of females will develop endometrial cancer due to mutations 
in the mismatch repair pathway [11].  
 
The development of CRC involves a number of steps, where environmental factors 
and endogenous carcinogens provoke initiation and proliferation of cells within the 
colon [13]. This causes the activation of oncogenes and the inactivation of tumour 
suppressor genes [14]. CRC is known as a multifactorial disease which suggests that 
many underlying processes influence cancer progression [12, 13] and these include 
genetic and environmental factors.  
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1.1.1 History of HNPCC  
The predisposition of some families to develop cancer at a young age was first 
recognised by Alfred Warthin in 1895, when his seamstress, from her family history, 
predicted her own death from cancer [5]. By studying her family extensively he found 
that gynaecological, colonic and stomach cancer occurred frequently [5]. However it 
was not until the 1980s that the idea of cancer family syndromes became fully 
accepted and the term Lynch syndrome was first used [5]. Lynch syndrome was first 
divided into type I and type II, depending on whether individuals developed extra-
colonic cancers [5]. Later when it was discovered that both of these syndromes were 
due to the inherited defects in the genes that regulate the excision of errors occurring 
during DNA replication (mismatch repair genes), it became clear that they were 
manifestations of the same disease [5]. Both syndromes are usually referred to as 
HNPCC, but the term Lynch syndrome is still used [5].   
1.1.2 Clinical findings 
The term Hereditary Non-Polyposis Colorectal Cancer indicates that there are no 
polyps present in those patients diagnosed with the syndrome. This is however not the 
case as a small number of polyps can be present in up to 30 per cent of affected 
patients [15-17].The polyps associated with HNPCC tend to occur at an early age and 
are larger in size than in the general bowel cancer population [5].  
1.1.3 Diagnosis of HNPCC 
Family history is the primary method used for identifying patients/families for 
HNPCC testing [9]. The diagnosis of HNPCC is based on the meeting of four criteria, 
known as the Amsterdam criteria (listed below), which originally derived as an aid in 
identifying the genetic basis of the disease.    
 
Amsterdam criteria for HNPCC patients: 
1) Three or more relatives with histological verified colorectal cancer, one of 
whom is the first degree relative of the other two. 
2) Colorectal cancer involving at least two successive generations. 
3) At least one relative diagnosed with colorectal cancer under the age of 50. 
4) Exclusion of familial adenomatous polyposis [4, 9, 18]. 
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Since nearly 60 per cent of families failed to fit every criterion due to the appearance 
of extracolonic cancer, they were revised in 1999 (Amsterdam criteria II), to also 
include the cancers of the endometrium, ureter, renal pelvis and small bowel [19].  
Families found to meet all criteria have a greater probability of being diagnosed with 
HNPCC syndrome. It is important to recognise these characteristics and offer genetic 
testing and counselling to those being affected with the syndrome [9]. The Bethesda 
guidelines, developed in 1996, are similar to the Amsterdam criteria. However, the 
major difference is that the Bethesda criteria aims to test patient’s tumours for 
microsatellite instability before screening for mutations in the MMR genes [20, 21]. 
Both, the Amsterdam and Bethesda criteria are clinically used to diagnose possible 
HNPCC patients [20].  
       
1.2 DNA Mismatch Repair Genes 
HNPCC is caused by germline mutations in DNA mismatch repair (MMR) genes 
[22]. In HNPCC patients at least four DNA mismatch repair (MMR) genes have been 
associated with the disease: hMSH2, hMLH1, hMSH6 and PMS2, with the majority 
affecting hMLH1 and hMSH2 [1-4, 23]. Germline mutations in one of these 4 MMR 
genes, are detected in 70%-80% of families diagnosed with HNPCC [24]. More than 
400 different predisposing MMR gene mutation are known, with approximately 50% 
affecting hMLH1, 40% hMSH2, 10% hMSH6 and less than 5% affecting PMS2 [24]. 
If a somatic mutation inactivates the remaining wild type allele, the affected cell will 
potentially accumulate new mutations at a very high rate [7]. This will enhance the 
potential for malignant transformation and the possibility to of developing cancer [7].  
 
The names of the mismatch repair genes associated with HNPCC were a result of 
their structural similarity to the bacterial proteins, known as MutS, MutL and MutH 
and postmeiotic segregation (PMS2) [25-27]. The reason for this being the mismatch 
repair system was first studied in bacteria [27]. hMSH2 and hMSH6 are both similar 
to the bacteria protein MutS and is an abbreviation of human MutS Homolog, as well 
as the hMLH1 is an abbreviation of human MutL Homolog. The postmeiotic 
segregation (PMS2) gene was named before the function of the protein was elucidated 
[26].  
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1.2.1 Germline mutation  
The principle behind inherited genetic risk is based on Knudson’s ‘two hit’ 
hypothesis. All somatic cells contain two copies (or alleles) of any gene, therefore 
both alleles must be disrupted or ‘hit’ before genetic function is altered [14, 28]. 
Patients with an inherited risk of cancer due to a diagnosis of HNPCC are born with 
one defective copy of a gene, inherited from a parent. This is known as a germline 
mutation. Individuals at risk only require a somatic mutation in the remaining normal 
allele before gene function is lost and thereby alter the risk of disease development in 
the HNPCC population [14, 29], which explains the lower age of onset of cancer in 
the HNPCC population.   
 
1.3 DNA damage and DNA repair 
DNA is constantly exposed to external and internal mutagenic agents, for example 
free radicals, ionising agents, UV light and different kinds of toxins [30, 31]. These 
agents can among others potentially affect the integrity of the genome [30, 31]. If 
DNA damage fails to be repaired, it will result in DNA mutations [31]. It is therefore 
extremely important that the DNA repair systems are working efficiently so they can 
respond to DNA damage at any time.  
 
DNA damage response (DDR) consists of numerous of signalling events crucial for 
sensing DNA damage [32]. The major role of the DDR, in response to DNA damage, 
is to activate cellular responses such as cell cycle arrest, DNA repair, senescence and 
apoptosis [32]. Since the human cell is exposed to many agents that can cause damage 
to the genetic code [33], it is necessary to have an efficient DNA repair system. In 
response to this, cells have developed five different pathways in which DNA damage 
can be detected and repaired [31]. One of these major pathways is mismatch repair 
(MMR). Failure to repair DNA lesions can lead to unregulated cell growth and 




1.4 Human DNA Mismatch Repair 
The primary function of the MMR system is to eliminate base-base mismatches and 
insertion-deletion loops which arise as a consequence of DNA polymerase slippage 
during DNA replication [4]. These lesions typically affect non repetitive DNA leading 
to single base substitutions (for example G→T) and it also involves gains or losses of 
short repeat units (for example CACA) [4]. In humans, at least six different MMR 
proteins are required to recognise mismatches [4]. Mismatch recognition is mediated 
by either one of the two heterodimers MutSα or MutSβ. The MutSα is composed of 
the MutS homologs MSH2 and MSH6, while the MutSβ is composed of the MutS 
homologs MSH2 and MSH3 [34]. The MSH2-MSH6 heteroduplex, known as MutSα, 
identifies single-base mispairs and initiates excision of the mismatch base [5, 34]. The 
MSH2-MSH3 heteroduplex, known as MutSβ, predominantly recognizes larger DNA 
insertion loops [5, 34].  
  
The interplay between MLH1 and PMS2 (known as MutLα), coordinates which 
mismatch recognition complex (either MutSα or MutSβ) that is necessary for MMR 
[4]. In humans, the PMS2 subunit within the MutLα complex possesses endonuclease 
activity which enables MutLα to insert random nicks at sites spanning the mismatch 
[34]. This leads to the activation of exonuclease (EXO1) in the direction 5`-3`, which 
removes the incorrect DNA fragment [34]. The remaining single-stranded gap is filled 
with polymerase δ and its cofactors, proliferation cell nuclear antigen (PCNA) and 
replication factor C (RFC) [34]. The mismatch repair is finished when the nicks are 
sealed by DNA ligase I [34]. See figure 1.1 for the MMR pathway.    
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Figure 1.1: Mismatch repair pathway. The MSH2-MSH6 heteroduplex (MutSα) recognises 
single base mispairs and recruits heterodimer MLH1 and PMS2 to initiate repair of the DNA 
damage. The MSH2-MSH3 heteroduplex (MutSβ) recruits MLH1 and PMS2 to initiate repair 
of larger insertion deletion loops [5].  
 
1.5 Microsatellite instability (MSI) 
Nearly all HNPCC tumours display microsatellite instability (MSI) [21]. 
Microsatellite instability is a genetic signature of a tumour tissue that occurs as a 
result of DNA mismatch repair deficiency. Microsatellites are repetitive nucleotide 
sequences dispersed throughout the human genome [7]. These sequences do not code 
for any proteins and their function still remains largely unknown [5]. Mutations in 
MMR genes give rise to alterations in the number of repeat units in these sequences of 
DNA and thereby confer instability on the genome [9]. For this reason they are useful 
in detecting damage to DNA repair systems. MSI is defined as: “a change of any 
length due to either insertions or deletions of repeating units in a microsatellite within 
a tumour compared to normal tissue” and results from failure of the cell to repair 
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errors made during DNA replication [21]. Such errors are usually repaired by MMR 
proteins [24]. A defect in MMR genes allows errors to accumulate which will increase 
the risk of malignant transformation of the cells and MSI to develop [24]. If MSI is 
detected in a tumour sample it is likely that the individual will harbour a MMR gene 
mutation.  MSI testing is often performed before screening for a mutation to decide 
which gene to test for as this is more efficient in terms of cost and time. However, 
MSI testing can not replace screening for mutations in MMR genes as not all HNPCC 
tumours display MSI. It should be noted as well that approximately 15% of all 
colorectal cancers display MSI.  
 
1.7 Single Nucleotide Polymorphisms (SNPs)  
Approximately 90% of all human genetic variation are differences in single bases of 
DNA, called single nucleotide polymorphisms (SNPs) [35]. For a variation to be 
defined a SNP it must occur with a frequency of at least 1 % in a given population 
[36, 37]. A SNP (pronounced “snip”) [37] occurs within a DNA sequence and appears 
when a single nucleotide, for example A is being replaced by one of the three other 
nucleotides- T, G or C. SNPs are found within the coding regions (exon) of genes, in 
the non coding regions (intron) or in the intergenic regions between genes. Although 
SNPs in the coding region are more likely to cause functional changes than SNPs 
elsewhere, not every SNP will affect gene function [35]. In fact, certain SNPs do not 
cause an increased risk of cancer as the amino acid that the SNP encodes will be the 
same as the amino acid in the absence of the SNP [38]. Some SNPs cause a change in 
the amino acid (also known as missense mutations) but the functional significance 
needs to be investigated to determine whether a change in amino acid affects protein 
function. SNPs that encode stop codons are also known as nonsense mutations, 
usually lead to a severely altered and potentially non functional protein [38]. 
Insertions or deletions cause the frame of the sequence to be altered which can lead to 
a translation error and results in the loss of protein function [38].  
 
The human genome is estimated to contain one single polymorphism (SNP) for every 
300 base pairs [39]. Overall, this accounts for a total of several million SNPs [40]. 
SNPs are therefore extremely important in the study of structure and history of the 
human genome [40]. SNPs can in fact, be directly responsible for genetic diseases, as 
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they may alter the genetic sequence of a regulatory region [41]. Since most SNPs are 
inherited from one generation to the next; they also represent a powerful tool to study 
the evolution of our species [41]. With many SNPs yet to be detected, large scale 
databases of SNPs have been developed over the years growing rapidly every day 
[37]. The main purpose of gathering SNP data in an accessible database is to make it 
possible for researchers around the world to perform association studies.  
 
1.8 Association studies 
The aim of association studies is to find a connection between SNP alleles and the 
development of certain diseases by investigating polymorphisms in possible causative 
candidate genes (modifier genes) [41]. This is accomplished by comparing two 
populations which are different from one another in terms of phenotype [41]. By 
measuring the frequency of SNPs in both populations one can detect those SNPs that 
show significant difference in frequency [41]. If there is evidence to suggest that a 
polymorphism in a gene increases the risk of disease, that polymorphism should be 
found at a significantly different frequency in those individuals with the disease 
compared to healthy controls [37]. This can also be applied for non-genetic factors, 
such as smoking which is associated with lung cancer [37]. Since association studies 
can help us to better understand development of disease and disease onset, SNPs have 
received a considerable amount of attention as they are being widely used in studies 
that focus on the effect of modifier genes in disease [41].  
 
1.9 Modifier genes 
A gene existing in two or more different forms or alleles within a population is said to 
be polymorphic. A polymorphic gene can also be referred to as a modifier gene, as 
modifier genes have the ability to alter the function of a gene and ultimately change 
the phenotypic expression [13]. Modifier genes can influence the frequency of 
expression of an allele and the variation in allelic expression from one individual to 
another [13]. They are also responsible for a phenomenon where a single gene is 
responsible for a number of distinct and seemingly unrelated phenotypic diseases 
[42]. This is the case for HNPCC families with a known mutation, where the disease 
expression varies between individuals that have the same mutation [43]. Some 
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individuals will therefore develop disease earlier, while others might not develop 
cancer at all. Different types of cancers can also be seen in patients with the same 
mutation as well as the intensity of the disease. This indicates that other genes 
(modifier genes) are likely to influence disease expression [44].  
1.9.1 The role of modifier genes in HNPCC 
Any human disease cannot be explained ultimately by a single gene [45] [46] [5]. In 
HNPCC patients there is considerable variation in disease expression (such as age of 
diagnosis and tumour site) which cannot be entirely explained by the type and 
position of the mutation in MMR genes. Several reports have shown that genetic 
modifiers may contribute to disease in HNPCC [47-49].  
 
Single nucleotide polymorphisms (SNP) in the TP53 gene have been associated with 
the age of onset of CRC in HNPCC patients [50]. TP53 is a tumour suppressor gene, 
which regulates the transcription of genes necessary to maintain genomic stability. 
The role of tumour suppressor genes is to initiate apoptosis in cancer cells and 
blocking cell proliferation and cell growth after DNA damage [14, 51]. HNPCC 
patients heterozygous for the wild type allele in the R72P SNP developed colorectal 
cancer at an average age of 13 years younger than those who where homozygote wild 
type for this particular allele [50]. However, controversial reports have been reported 
by Talseth et al. 2006 suggesting that the age of diagnosis of CRC in HNPCC is more 
complex than predicted by R72P polymorphisms in TP53 [44].  
 
Two single nucleotide polymorphisms (SNPs) in genes involved in the cell-cycle, 
Aurora A and Cyclin D1, have also been associated with the age of onset of CRC in 
HNPCC patients [44, 52 Kong, 2000 #81] HNPCC patients homozygous for the wild 
type allele (TT) of the T91A SNP (F31I) in Aurora-A developed CRC approximately 
7 years earlier than patients carrying the variant allele [52]. Aurora-A is involved in 
normal cell cycle, but is overexpressed in a variety of malignancies [53].  Aurora-A 
regulates the G2-to-M phase of the cell cycle [54]. If DNA damage occurs the 
activation of Aurora-A is inhibited [54]. It is believed that DNA repair might be 
involved in cell cycle control as it has been suggested that MMR genes are necessary 
to activate G2-M checkpoint in the presence of certain types of DNA damage [55].    
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For the 870 G>A SNP in Cyclin D1 patients with the variant allele were associated 
with an earlier age of disease diagnosis by an average of 11 years compared to 
patients homozygous for the wild type allele [56]. Cyclin D1 has an important role in 
the G1-to-S phase in the cell cycle [57]. However, the relationship between Cyclin D1 
and disease expression appears to be more complex than first predicted. While one 
study shows an association between the polymorphism and the age of disease onset 
[56], another study from Finland failed to show a similar relationship [58]. The major 
difference between the two studies was the predominance hMSH2 carriers in one 
population compared to hMLH1 carriers in the other. To better understand the 
relationship between disease phenotype and certain types of polymorphisms large 
groups of HNPCC patients are required.    
1.9.2 Why search for modifier genes in HNPCC? 
In the context of human disease modifier genes have been defined as inherited genetic 
variation which can change one person’s phenotype either quantitatively or 
qualitatively [59]. The search for modifier genes is important because it makes it 
possible to provide more specific diagnosis of disease risk in HNPCC patients. 
Identification and removal of colorectal adenomas (as well as other types of polyps) 
will almost certainly reduce the incidence of developing cancer [60]. Therefore if 
modifier genes affecting your risk of developing CRC are found in HNPCC patients, 
early screening can be initiated to reduce the incidence of disease development and 
progression. In addition, the identification of modifier genes associated with disease 
will also help to optimize the response to drug treatment in individuals [61]. Currently 
there are no frequent, regular and effective screening methods for colorectal tumours 
in the general population [60]. The challenge is therefore, to determine whether 
particular SNPs in genes affect the function of specific proteins involved in HNPCC. 
This is of great interest as the discovery of modifier genes influencing disease 
expression in HNPCC can be useful for genetic testing.  
1.9.3 Benefits of identifying modifier genes 
There are two major benefits of identifying modifier genes in HNPCC patients at an 
early age [60]. Firstly, those patients carrying specific modifiers would initially be 
screened regularly for any abnormalities. Secondly, it is a unique way to understand 
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cancer biology by knowing how mutations in different genes interact in the genetic 
pathways of tumorgenesis [60].  
 
1.10 Candidate modifier genes 
The SNPs studied in this project were chosen since they have previously been linked 
to cancer development. The decision to look at these specific SNPs were based on 
several genome wide association studies that revealed a number of colorectal cancer 
susceptibility loci on chromosome 10p14, 8q23.3, 8q24, 11q23 and 15q13. These loci 
are of particular importance as they are associated with an increased risk of 
developing CRC. The SNPs elected may therefore act as modifiers of disease risk in 
individuals diagnosed with HNPCC. The SNPs are to be found within or close to a 
variety of genes: EIF3, SMAD7, GREM1, SCG5, POU5F1P1, BC031880, 
LOC38996, LOC120376 and FLJ45803.   
1.10.1 Eukaryotic initiation factor 3 (EIF3) 
SNP rs16892766 is located on chromosome 8q23.3 within the subunit H of the EIF3 
gene [62]. Translation initiation is controlled by numerous different translation factors 
and the most important one is the eukaryotic translation initiation factor 3 (EIF3) [63]. 
Translation initiation is an important step in the regulation of gene expression in 
eukaryotes [63]. Deregulation at this step causes abnormal gene expression, leading to 
altered cell growth and possibly cancer [63]. Cells that contain high levels of the H 
subunit, which is a protein subunit of EIF3, have been associated with different types 
of cancers [64]. Overexpression of EIF3H leads to strongly translated mRNAs, 
affecting translation, proliferation and a number of malignant phenotypes [64]. The 
failure to down-regulate protein synthesis leads to an overproduction of oncogenic 
proteins, resulting in malignant transformation of cells [63].  
1.10.2 SMAD family member 7 (SMAD7) 
SMAD7 is located at chromosome 18q21 and a genome wide association study 
indicated that SNP rs4939827 and rs4464148 are associated with CRC [65]. The 
SMAD signalling pathway plays an important role in tumorigenesis and progression 
in cancer [66]. The protein level of SMAD is associated with growth, inhibition and 
metastasis in a variety of human cancers [66]. A previous study has shown that there 
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is overexpression of SMAD7 in gastric cancer tissue [66]. This overexpression of 
SMAD7 in colon cancer cells induces tumorigenicity by blocking transforming 
growth factor (TGF)-beta-induced growth inhibition and apoptosis [67, 68].  
1.10.3 Gremlin 1 (GREM1), cysteine knot superfamily 
SNP rs10318 is located within the GREM1 gene which encodes a secreted bone 
morphogenetic protein (BMP) antagonist. GREM1 has shown to be overexpressed in 
several of human tumours, as for instance carcinomas of the colon [69]. The TGF-
beta/BMP pathway is also known to have an important role in colorectal 
tumorigenesis [70]. It is therefore believed that GREM1 may increase tumour 
proliferation and thereby influence cancer development [71].  
1.10.4 Secretogranin (SCG5) V (7B2 protein) 
SNP rs4779584 lies between GREM1 and SCG5. SCG5 is a protein coding gene 
involved in neuroendocrine signalling which is thought to influence cellular 
proliferation [71]. A genome wide association study indicated that genetic variants at 
the 15q3.3 influence on colorectal cancer risk and SNPs near GREM1 and SCG5 were 
strongly associated with increased CRC risk [71]. SNP rs10318 and rs4779584 are 
both located on chromosome 15q13.3 [71]. 
1.10.5 POU class 5 homeobox 1 pseudogene (1 POU5F1P1) 
SNP rs6983267 is located near the POU5F1P1 pseudogene on chromosome 8q24.21. 
This gene acts as a transcriptional activator and has been shown to encode a protein. 
This SNP is associated with increased risk of colon and prostate cancer [27].  
 
SNP rs7014346 is also located on chromosome 8q24 but does not code for a protein. 
The SNP is located near the POU5F1P1 pseudogene, however its function is not well 
understood [72]. A genome wide association study has suggested an association 
between the particular loci and CRC [72].     
1.10.6 BC031880 and LOC38996 gene 
SNP rs10795668 is not found within any gene, but is thought to be near the 
BC031880 and the LOC38996 gene [62]. This SNP is located at chromosome 10q14 
and a recent study has shown that this SNP is associated with CRC [62].  
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1.10.6 LOC120376 and FLJ45803 gene 
SNP rs3802842 is found within the LOC120376 and FLJ45803 genes on chromosome 
11q23 [72]. This SNP has recently been reported to show population differences in 


















1.11 Aims and hypothesis of the Study 
Mutations in the four mismatch repair (MMR) genes; hMLH1, hMSH2, hMSH6 and 
PMS2 are already known to be associated with HNPCC. The identification of 
predisposing mutations in these genes has demonstrated some genotype-phenotype 
correlation. However, there is still significant phenotypic variation among individuals 
with HNPCC. In fact, the age of diagnosis, severity of disease and the appearance of 
extracolonic cancers vary within families and between families that harbour the same 
mutation. The explanation for this disease variation is thought to be due to 
polymorphisms in modifier genes.  
 
Recently, several genome wide association studies have revealed a number of 
colorectal cancer susceptibility loci on four chromosomes; 10p14, 8q23.3, 8q24, 
11q23 and 15q13. Since these loci have been associated with an increased risk of 
sporadic CRC, they may also influence the cancer development modifiers in HNPCC 
patients.  
 
The study hypothesis is that polymorphisms in modifier genes influence disease 
expression in HNPCC patients carrying a mutation in hMLH1, hMSH6 or hMSH2. 
The identification of polymorphisms with modifying effect can help to predict with 
more accuracy the type of cancer and age of disease onset in individuals harbouring 
the syndrome.  
 
The aim of this project is to examining 373 Australian and 311 Polish HNPCC 
patients with a molecular diagnosis of HNPCC (mutation positive) for nine different 
polymorphisms in the five loci described above to determine if these polymorphisms 








2 MATERIALS AND METHODS 
2.1 Materials 
The reagents and equipment used in this study are stated in the appendix 1.  
 
2.2 HNPCC Participant Information 
Patients diagnosed with HNPCC were selected for this study. The selection criteria 
were based on the molecular diagnosis of HNPCC. All patients harboured a mutation 
in one of the mismatch repair (MMR) genes, hMLH1, hMSH2 or hMSH6. All the 
patients were of Caucasian origin, but divided into two subpopulations according to 
the country in which the samples were collected, Australia or Poland.  
2.2.1 Australian Population  
373 samples were collected in the state of New South Wales, Australia. Of the 373 
individuals, 165 (44%) had been diagnosed with colorectal cancer while 202 (54%) 
were not affected with colorectal cancer. In 6 (2%) of the cases it was unknown if the 
participant were affected with colorectal cancer or not. There were 25 (7%) affected 
with endometrial cancer, 7 (1.9%) with ovarian cancer, 7 (1.9%) with breast cancer, 5 
(1.3%) with kidney cancer, 4 (1.1%) with melanoma, 4 (1.1%) with stomach, 3 with 
bladder and 2 with pancreatic cancer, which together account for less than 1%. 
Among the 165 affected with CRC, 22 (13%) had a recurrent CRC. There were a total 
of 221 (59%) females and 150 (40%) males. For 2 (1%) of the participant gender was 
unknown. There were 184 (49%) cases with germline hMLH1 mutation, 164 (44%) 
with hMSH2 and 25 (7%) with hMSH6. Of these mutation carriers there were 355 
(95%) nonsense insertion, deletion or splice mutation (leading to a truncated protein) 
and 18 (5%) with missense mutation. All of the missense mutations were in the 
hMLH1 mutation carriers.  
2.2.2 Polish Population  
311 samples were collected from the Pomerian Academy of Medicine, Poland. Of the 
311 individuals, 121 (39%) were affected with CRC while 190 (61%) were unaffected 
with CRC. Among the 121 affected with CRC, 10 (8%) had a recurrent CRC. Other 
types of cancer that could be seen within the Polish population were; 38 (12.2%) 
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individuals with endometrial cancer, 6 (1.9%) with ovarian, 3 with bladder, 2 with 
breast, 2 with kidney, 2 with stomach, 1 with lung and 1 with cervical cancer, in 
which all accounts for less than 1% of the cases. There were a total of 189 (61%) 
females and 122 (39%) males. In the Polish samples there were 172 (55%) with 
hMLH1 mutation, 114 (37%) with hMSH2 and 25 (8%) with hMSH6. There were no 
cases with missense mutation.  
2.2.3 Ethical Consideration  
All participants had given written consent for their DNA to be used for further ethics 
approved research into the cause of their condition at the time of counselling. HNPCC 
samples were supplied from the state centre for colorectal testing. Approval for this 
study was obtained from Hunter New England Health Research Ethics Committee 
(Australia), the Human Research Ethics Committee at the University of Newcastle 
(Australia) and the Ethics Committee of the Pomeranian Academy of Medicine 
(Poland).    
2.2.4 Sample Groups 
Altogether, 684 samples were genotyped in this study. To determine any association 
between the disease characteristics and polymorphisms investigated, the samples were 
subdivided into different subgroups according to:  
I. Their gene mutation status (hMLH1, hMSH2 or hMSH6) 
II. Disease expression (affected with CRC, unaffected with CRC and affected with 
gynaecological cancer *) 
III. Gender (female or male) 
* Females that were affected with endometrial cancer and ovarian cancer were placed 
into the same group called gynaecological cancer.          
 
Each individual had previously contributed blood from which DNA was extracted 
using the salt precipitation method. Each DNA sample was diluted to a concentration 




All DNA samples were genotyped to determine the genotype frequency in the nine 
single nucleotide polymorphisms (SNPs) investigated. Three different genotypes were 
obtained for each SNP: Homozygous wild type, where the sample did not contain the 
variant allele; heterozygous, where one allele had the variant allele and homozygous 
mutant, where both alleles harboured the variant allele. For example, SNP rs16892766 
harbours a change of A to C, where the homozygous wild type is AA, the 
heterozygous is AC and the homozygous variant is CC. The letters A and C refers to 
the nucleotide present at the polymorphic site.  
 
2.4 The Principle behind Real time PCR 
Real time PCR is a high throughput technique that detects and quantitates 
fluorescence released from probes bound to nucleic acid sequence  [74] [75]. The ABI 
PRISM® 7900HT (Applied Biosystems) machine distributes light from an argonic 
laser that excites samples in each well.  The resulting fluorescence is captured by a 
charge couple device camera where fluorescence is detected between 500nm and 
600nm [76]. This allows the CCD camera to capture fluorescence of multiple 
fluorophores [76, 77].  
 
The real time PCR method used in this study uses two TaqMan probes that differ at 
the polymorphic site and carry a different 5’ fluorophore. The probes are 
approximately 20 base pair (bp) sequences that are designed over the region of the 
SNP. One probe has the complementary sequence of the wild type allele and the other 
has the complementary sequence of the variant allele. A 5’ reporter dye and a 3’ 
quencher dye are covalently linked to the probes [78]. During the PCR annealing step, 
the probe binds specifically to the target polymorphic site [78]. If a probe binds to the 
polymorphic site, the 5’ reporter is cleaved by the nuclease activity of the Taq 
polymerase which increases the characteristic fluorescence of the reporter dye [79,  
#99]. When a probe does not bind to the target site, the 3’ quencher decreases the 
fluorescence of the 5’ reporter, thereby minimizing background fluorescence[78].  
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The amount of amplified PCR product increases exponentially during PCR because 
after each successive cycle the probe is able to bind more DNA copies, which then 
increases the reporter fluorescence (Figure 2.2) [79]. Sequence detection system 
(SDS) software quantifies and compares the fluorescence signal which makes it 
possible to determine the allelic content of each sample on the plate. The values of the 
fluorescence in each well are plotted in a graph and it can then be determined whether 





Figure 2.1: Chemistry of TaqMan real time PCR reactions. When the probe successfully 
binds to the target sequence, fluorescence is released from the TaqMan reporter probe. 




Figure 2.2: Amplification plot. The amplification of DNA can be viewed using real time 
PCR. The upper blue line shows the amplification of the wild type allele in the DNA while 




Figure 2.3: Allelic discrimination graph. The allelic discrimination graph shows difference 
in fluorescence between the wild type, heterozygous and variant which makes it possible to 




2.5.1 Design of primers and probes for RT-PCR 
Primers and probes for the SNPs rs4939827, rs4464148, rs6983267, rs16892766, 
rs10795668, rs3802842, rs7014346, rs4779584 and rs10318 were designed by Assay-
on-Demand which is a service offered by Applied Biosystems (PE Applied 
Biosystems). The nine SNPs and their respective NCBI reference, assay ID, allele, 
chromosome and gene are shown in table 2.1. 
 
Table 2.1: SNP information. Listed below are the nine SNPs and their NCBI reference, 
assay ID, alleles, chromosome and gene.     
NCBI SNP Reference Assay ID Alleles Chromosome Gene 
rs16892766 C_32670283_10 A>C Chr 8 EIF3H 
rs3802842 C_27503482_10 A>C Chr 11 LOC120376;FLJ45803 
rs10318 C_12070332_20 C>T Chr 15 GREM1 
rs4939827 C_27913406_10 C>T Chr 18 SMAD 7 
rs4464148 C_27989234_10 T>C Chr 18 SMAD 7 
rs6983267 C_29086771_20 T>G Chr 8 POU5F1P1 
rs7014346 C_29086780_10 G>A Chr 8 POU5F1P1 
rs4779584 C_28019826_10 C>T Chr 15 SCG5 
rs10795668 C_1779559_10 G>A Chr 10 BC031880; LOC38996 
 
Approximately 250bp of the DNA sequence either side of the SNP was sent to 
Applied Biosystems which was used to design the appropriate primers and probes, 
which are also tested and validated by the company. The context sequence for each 













Table 2.2: Context sequence. Context sequence from Assay-on-Demand Service for the nine 
polymorphisms 
rs16892766   
Reverse 
Sequence  5' AGACGCAAACAGTTTCAAGACTATT[A/C]GCTGTTAAAGGTTATGCCTTATGTC 
rs3802842   
Forward 
Sequence 5' GCCCTTGCAGACCCATAGAAAATCT[A/C]TCCCAGAAATTCACCTCATTTTAGG 
rs10318   
Forward 
Sequence 5' AAGATATTTGTGGTCTTGATCATAC[C/T]TATTAAAATAATGCCAAACACCAAA 
rs4939827   
Forward 
Sequence 5' TCACAGCCTCATCCAAAAGAGGAAA[C/T]AGGACCCCAGAGCTCCCTCAGACTC 
rs4464148   
Reverse 
Sequence  5' GGGGGAACAGACAGAGAAGGATGAA[C/T]GTGAAAAGGAAACACCCTGGTAACT 
rs6983267   
Forward 
Sequence 5' GTCCTTTGAGCTCAGCAGATGAAAG[G/T]CACTGAGAAAAGTACAAAGAATTTT 
rs7014346   
Forward 
Sequence 5' TCAAGATGGCTTCTGGAGTGCTACC[A/G]TTACATCCATGTTGTAGGCTAGAAG 
rs4779584   
Reverse 
Sequence  5' AGAACTTGTTGATAAGCCATTCTTC[C/T]GAACAGAAACCATAACTATACACAC 
rs10795668   
Reverse 
Sequence  5' AGAAAGAGAAAAAGTTAGATTCTTA[A/G]ATTCCATGATTTTATATTTCCCACC 
 
2.5.2 Initial run of RT-PCR 
All Assays-by-Demand reactions work under the same conditions and a test reaction 
of each SNP was performed prior to sample analysis to confirm this. Each reaction 
contained: 1ηg DNA, 0.125μL Assay (Applied Biosystems) and 2.5μL TaqMan 
Universal PCR master mix (Applied Biosystems). The reaction was made up to a final 
volume of 5μL using MilliQ water (Millipore North Ryde, Australia). The PCR 
reaction was conducted using the ABI PRISM® 7900HT sequencing detection system 
set to the following conditions: 50ºC for 2 minutes, 95ºC for 10 minutes and 40 cycles 
of 92ºC for 15 seconds and 60ºC for 1 minute. After the PCR amplification, the plate 
was scanned to detect fluorescence in each well to generate a graph. The graph is 
converted to a scatterplot which displays wild type reporter fluorescence versus 
mutant reporter fluorescence. Low fluorescence was detected during optimisation of 
some SNPs and this was adjusted by increasing the number of cycles from 40 to 60. 
For each SNP the volume of the reaction was set to 5μL. 
 32
2.5.3 Qualitative analysis of SNPs  
After successful optimisation of reaction conditions the samples were genotyped in 
96-well optical reaction plates (Applied Biosystems and Axygen Scientific (Union 
City, CA, USA)). The reagents and volumes used for each assay are shown in table 
2.3. Each plate contained three controls: homozygous wild type, heterozygous and 
homozygous variant. Each plate also contained two no-template controls where sterile 
water was used in place of DNA (negative control). In addition there were three 
controls with known genotype to make sure that the run worked properly each time. 
The remaining wells contained samples with unknown genotype. If the DNA did not 
produce any fluorescence, genotyping was performed a second time. If the reaction 
did not work after a second attempt, the DNA sample was taken out of the study for 
the particular SNP. Therefore different sample numbers can be seen between the same 
groups for different SNPs. ABI PRISM® 7900 HT sequencing detection system 
(Applied Biosystems) was used for thermal cycling and the allelic discrimination 
(AD) for each plate.   
 
Table 2.3: Reaction components of a genotyping reaction. Listed below are the volumes of 
each reagent in one reaction. 
Reagents Volume in 1 reaction 
TaqMan Universal PCR Master Mix 2,5μL 
Assay-by-design (40X) Primers and Probes 0.125μL 
MilliQ water 1.375μL 
DNA (50ηg/μL) 1μL 
Reaction Volume per Sample 5μL 
 
2.6 Statistical Analysis 
Statistical analysis was performed to determine whether particular single nucleotide 
polymorphisms are associated with specific types of disease expression or age of 
survival in HNPCC patients. The genotype frequency of all polymorphisms studied 
were analysed using the statistical software package SPSS Graduate Pack Version 
12.0 (SPSS Incorporated, Chicago, IL USA). The chi-squared test was used to see if 
differences within the subgroups described in section 2.2.4 are statistically significant, 
while the Kaplan Meier survival analysis was used to compare genotype and age of 
diagnosis of CRC in HNPCC patients. The significance level was set at p<0.05 for all 
 33
tests performed and the confidence interval (CI) was set to 95%. This test measures 
the probability value (p value), which is the likelihood that a certain range data is 
found within 95% of the population. Odds ratio was calculated for significantly 
different results (for 2x2 tables).  
2.6.1 Determining allele frequency distribution  
After determining the genotype of the nine polymorphisms in each sample, the 
genotype frequency was examined in subgroup I, II and III, described in section 2.3.4. 
For the three groups, the genotype frequency was assessed in all HNPCC individuals 
in both the Australian and Polish population separately. Genotypes from the 
Australian and Polish populations were then combined to perform the exact same 
analysis. Pearson’s Chi-squared test was used to assess the distribution of the 
genotypes if the genotype frequency was >5 and Fisher’s exact test was used for <5. 
Three different genotypes were obtained for each SNP examined. In addition to 
compare the three different genotypes to one another, a combination of two genotypes 
were also performed. Therefore, for each analysis performed three different results (p-
values) can be obtained. The three genotypes homozygous wild type (AA), 
heterozygous (Aa) and homozygous mutant (aa) was grouped as followed:   
- 1. analysis: AA versus Aa versus aa 
- 2. analysis: Aa + aa versus AA 
- 3. analysis: Aa + AA versus aa 
2.6.2 Genotype and colorectal cancer risk  
The genotype frequency of individuals affected with colorectal cancer (CRC) was 
compared to individuals unaffected with CRC to see if the genotype frequency varied 
between the groups.  
2.6.3 Genotype and MMR gene  
HNPCC individuals were subdivided into groups depending on MMR gene mutation, 
harbouring a mutation in hMLH1, hMSH2 or hMSH6. In the hMSH6 group there 
were only 50 patients and therefore not enough statistical power to analyse this group 
to hMLH1 and hMSH2 mutation carriers. The genotype frequency of hMLH1 
mutation carriers was compared to hMSH2 mutation carriers to see if there were any 
differences between patients with mutations in different MMR genes.  
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2.6.4 Genotype and gender  
Male HNPCC patients were compared to female HNPCC patients to observe if there 
were any differences in genotype frequency between genders.  
2.6.5 Genotype and gynaecological cancer risk  
Female HNPCC patients were subdivided into groups depending on whether they 
were unaffected or affected with either endometrial or ovarian cancer. Females 
affected with endometrial or ovarian cancer were placed into the same group called 
gynaecological cancer.  
2.6.6 Kaplan- Meier survival analysis  
Kaplan–Meier survival curves were used to plot the participants (cancer or not) versus 
the patient age of diagnosis of CRC/age of unaffected in relation to the genotype for 
each SNP examined. The Kaplan–Meier survival curves for each genotype were 
tested to see if there were differences in age of diagnosis of CRC by genotype. 
Comparison between the three different genotypes obtained from each SNP was 
performed by the Log Rank test. Two other non-parametric linear rank tests were also 
added to the analysis, the Breslow and Tarone-Ware tests. All tests were used to 
assess the equality of the survivor function across the three genotypes. The Breslow 
(generalized Wilcoxon) test was used to determine the significance of observation 
from early ages of diagnosis while the Log Rank test give more weight to later ages of 
diagnosis. The Tarone-Ware test, which is an intermediate of the two other tests, was 
also used to examine the homogeneity of the survival curve. Age of diagnosis was 
defined as patient age at the time of CRC diagnosis. For unaffected participant, age 
was based on the date of birth and disease free status at last consultation. For 
polymorphisms that showed a statistically significant difference between the 
genotypes and the age of survival, the odds ratio (OD) was calculated using 

























































The analysis of the relationship between single nucleotide polymorphisms (SNPs) and 
their association with disease development were undertaken with the following nine 
SNPs: rs4939827, rs4464148, rs6983267, rs16892766, rs10795668, rs3802842, 
rs7014346, rs4779584 and rs10318. All HNPCC samples were subdivided into the 
following groups and compared to each other:  
• Affected with CRC vs Unaffected with CRC 
• Affected with hMLH1 vs affected with hMSH2 
• Female vs male 
• Females affected with gynaecological cancer vs females unaffected with 
gynaecological cancer  
 
3.1 Genotype frequencies  
The genotype frequency distribution for every SNP was compared to determine if any 
significant difference existed between the various groups. We first analysed the 
Australian and Polish population separately (See appendix 3 and 4 for tables and 
figures). As there was no major significant difference in genotype frequencies 
between the Australian and Polish HNPCC participants, this allowed for pooling of 
the genotype results from the two populations. If the SNPs examined in this study are 
true modifiers, they are likely to influence the chance of developing disease HNPCC 
populations regardless of which country the samples are from. Therefore we 
combined the Australian and Polish data which presented us with excellent statistical 
power. The genotypes for the nine SNPs were determined by RT-PCR.  
 
3.2 Genotype distribution in the Australian HNPCC population  
The distribution of allele frequency of SNP rs4464148, rs7014346 and rs10795668 
within the different groups did not reveal any statistically association. See appendix 3, 
tables 5, 7 and 9. 
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The distribution of the genotypes for SNP rs16892766 among individuals affected 
with CRC differed from individuals unaffected with CRC (p=0.032), see appendix 3, 
table 1. No samples in the Australian population were homozygous variant for the 
rs16892766 polymorphism. A significant difference (p=0.044) in genotype frequency 
can be see for SNP rs10318 among individuals affected with CRC versus individuals 
unaffected with CRC when the homozygous variant genotype (TT) was compared to 
combination of heterozygous and homozygous wild type genotype (CT+CC), see 
appendix 3, table 3. 
 
The genotype frequency for SNP rs6983267 revealed a significant difference between 
individuals that harboured a mutation in the hMLH1 gene compared to individuals 
that harboured a mutation in the hMSH2 gene (p=0.012). A significantly different 
result (p=0.004) can also be seen for the same SNP when homozygous variant 
genotype (GG) was compared to heterozygous and wild type genotypes (TG+TT), see 
appendix 3, table 6. 
 
The genotype frequency differed significantly among females and males for three 
SNPs: rs4939827 (p=0.031), rs6983267 (p=0.030) and rs4779584 (p=0.043), see 
appendix 3, table 4, 6 and 8 respectively. For SNP rs4939827 and rs6983267 the 
difference can still be seen when the combination of heterozygous and homozygous 
variant genotypes are compared to homozygous wild type, p=0.010 and p=0.009 
respectively.  
 
SNP rs3802842 revealed a statistically different result (p=0.017) in genotype 
distribution in females affected with gynaecological cancer versus females not 
affected with the disease when the homozygous variant genotype (CC) was compared 




3.3 Kaplan-Meier survival analysis in the Australian HNPCC 
population 
The Kaplan-Meier survival analysis estimated by rs16892766 (SNP1) revealed a 
significant difference in the age of diagnosis of CRC between homozygous wild type 
genotypes (AA, 52-years) compared to heterozygous genotype (AC, 44-years), log-
rank test: p=0.004, Breslow test: p=0.014 and Tarone-Ware test: p=0.006. SNP1 also 
showed a significantly different result between homozygous wild type genotype (AA- 
52 years) compared to heterozygous genotype (AC-41 years) when comparing age of 
diagnosis of CRC in hMLH1 mutation carriers (log-rank test: p=0.001, Breslow test: 
p=0.001 and Tarone-Ware test: p=0.0008) but not in hMLH2 mutation carriers, see 
appendix 3, figure 1 and 2. 
 
A significantly difference can also be seen for rs3802842 (SNP2) in hMLH1 mutation 
carriers (log-rank test: p=0.003, Breslow test: p=0.013 and Tarone-Ware test: 
p=0.006), see figure 3.3 (AA-54 years, AC-50 years and CC-42 years). 
 
The Kaplan-Meier curves for rs4779584 (SNP8) show a significant result (log-rank 
test: p=0.021) when the wild type genotype (CC-50 years) was compared to the 
combination of heterozygous and variant genotypes (CT+TT-62 years). This finding 
can also be observed in hMSH2 mutation carriers; homozygous wild type genotype 
(CC, 49 years) compared to combination of heterozygous and variant genotype 
(CC+TT-64 years, see appendix 3 figure 5 and 6).   
 
Kaplan-Meier survival analysis estimated by rs7014346 (SNP7) genotype in hMSH2 
mutation carriers revealed a statistical significant difference between the genotypes 
(GG-45 years, GA-59 years and AA-56 years) and the age of diagnosis of CRC for 
the log-rank test: p=0.031 and when the wild type genotype (GG-45 years) was 
compared to combination of heterozygous and variant genotypes (GA+AA-59 years), 
see appendix 3, figure 3 and 4.  
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3.4 Genotype distribution in Polish HNPCC population  
The distribution of genotype frequency of SNP rs3802842 and rs4779584 within the 
different groups did not reveal any statistically associations, see appendix 4, tables 2 
and 8. 
 
The distribution of allele frequency for SNP rs16892766 among individuals affected 
with CRC differed from individuals unaffected with CRC (p=0.018) when the 
homozygous wild type (AA) was compared to combination of heterozygous (AC) and 
homozygous variant genotype (CC). See appendix 4, table 1. 
 
The genotype frequency differed among hMLH1 and hMSH2 mutation carriers for 
SNP rs49398727 (p=0.014) and rs7014346 (p=0.039), see appendix 3, table 4 and 7 
respectively. For SNP rs7014346 the homozygous wild type (GG) compared to the 
combination to combination of heterozygous (AC) and homozygous variant genotype 
(CC) was significantly (p=0.039) different, see appendix 4, table 1. 
 
The genotype frequency distribution of the rs10318 SNP differed among females and 
males, p=0.016. The difference can still be observed when homozygous wild type 
(CC) was compared to combination of heterozygous and homozygous variant 
genotypes (CT+TT) (p=0.012), see appendix 4, table 3. 
 
The genotype frequency of the rs10795668 polymorphism revealed a significant 
different result (p=0.036) among females and males when the homozygous variant 
genotype (AA) was compared to combination heterozygous and wild type genotypes 
(GA+GG). See appendix 4, table 9. 
 
The distribution of genotype frequency for SNP rs6983267 within the group of 
females affected with gynaecological cancer differed from females not affected with 
the disease revealed statistically significant results p=0.039. A significantly different 
result (p=0.034) can also be observed when examining wild type (TT) compared to 
combination of heterozygous and homozygous variant genotypes (TG+GG), and for 
homozygous variant (GG) genotype compared to combination of heterozygous and 
wild type genotypes (TG+TT), p=0.039, see appendix 4, table 6. 
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3.5 Kaplan-Meier survival analysis in the Polish HNPCC 
Kaplan-Meier survival analysis estimated by rs16892766 (SNP1) revealed a statistical 
significant difference between the genotypes (AA-53 years, the two other genotypes 
did not reach 50 %) and age of diagnosis of CRC (log-rank test: p=0.031) when age of 
diagnosis of CRC was examined, see appendix 4, figure 1. This is also true for 
hMLH1 mutation carriers who showed a statistical significant difference between the 
genotypes and age of diagnosis of CRC (log-rank test: p=0.023), see appendix 4, 
figure 2.  
 
A significantly different result can also be obtained for SNP2 rs3802842 between the 
genotypes (AA-53 years, AC-60 yeras and CC-44 years) and age of diagnosis of CRC 
(log-rank test: p=0.031, Breslow test: p=0.034 and the Tarone-Ware tests: p=0.030), 
see figure 3.4.  
 
3.6 Genotype distribution in the Australian and Polish HNPCC 
population combined  
The combined genotype distribution can be seen in table 3.1-3.9. When combining the 
Australian and Polish HNPCC population only one significant result can be observed 
when genotype frequency between all the different subgroups are compared. The 
rs4779584 SNP revealed a significant different result (p=0.038) in genotype 
distribution among females and males, see table 3.8. None of the other polymorphism 
investigated revealed any statistically association of allele frequency distribution (See 
table 3.1-3.7 and table 3.9). 
 
3.6 Combined Kaplan-Meier survival analysis 
Kaplan-Meier survival analysis estimated by rs3802842 (SNP2) revealed a highly 
statistical significant difference between the genotypes (AA-54 years, AC-53 years 
and CC-42 years) and age of diagnosis of CRC (log-rank test: p=0.0002, Breslow test: 
p=0.0005 and Tarone-Ware test: p=0.0003) when it comes to age of diagnosis of 
CRC, see figure 3.1. When homozygous variant genotype (CC-42 years) was 
compared to combination of heterozygous and wild type genotypes (AC+AA,-53 
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years), a significantly result was also observed. Log-rank test: p=0.0001, Breslow test: 








TABLE 3.1- ALLELE FREQUNCY DISTRIBUTION OF THE rs16892766 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=676)         
CRC+ (n=285) 241 (85) 44 (15) 0 44 (15) 285 (100) 






         
Subject group (n=630)         
hMLH1 (n=351) 299 (85) 52 (15) 0 52 (15) 350 (99.5) 






         
Subject group (n=679)         
Female (n=407) 351 (86) 56 (14) 0 56 (14) 406 (100) 






         
Subject group (n=406)         
Gynaecological+ (n=80) 67 (84) 13 (16) 0 13 (16) 80 (100) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (AA) compared to combination of heterozygous and homozygous variant 
genotypes (AC+CC) 
3p-value: Homozygous variant genotype (CC) compared to combination of wild type and heterozygous genotypes 
(AC+AA) 
* p-value was calculated using Fisher’s exact test 
 
 
TABLE 3.2- ALLELE FREQUNCY DISTRIBUTION OF THE rs3802842 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=670)         
CRC+ (n=283) 156 (55) 102 (36) 25 (9) 127 (45) 258 (91) 






         
Subject group (n=624)         
hMLH1 (n=345) 186 (54) 133 (39) 26 (7) 159 (46) 319 (93) 






         
Subject group (n=673)         
Female (n=402) 218 (54) 148 (37) 36 (9) 184 (46) 366 (91) 






         
Subject group (n=401)         
Gynaecological+ (n=79) 47 (60) 27 (34) 5 (6) 32 (40) 74 (94) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (AA) compared to combination of heterozygous and homozygous variant 
genotypes (AC+CC) 




TABLE 3.3- ALLELE FREQUNCY DISTRIBUTION OF THE rs10318 POLYMORPHISM IN THE 




























Allele frequency         
Subject group (n=662)         
CRC+ (n=278) 184 (66) 83 (30) 11 (4) 94 (34) 267 (96) 






         
Subject group (n=616)         
hMLH1 (n=340) 222 (65) 107 (32) 11 (3) 118 (35) 329 (97) 






         
Subject group (n=665)         
Female (n=398) 256 (64) 129 (33) 13 (3) 142 (36) 385 (97) 






         
Subject group (n=397)         
Gynaecological+ (n=78) 50 (64) 25 (32) 3 (4) 28 (36) 75 (96) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 
3p-value: Homozygous variant genotype (TT) compared to combination heterozygous and wild type genotypes 
(CT+CC) 
*p-value was calculated using Fisher’s exact test 
 
 
TABLE 3.4- ALLELE FREQUNCY DISTRIBUTION OF THE rs4939827 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=674)         
CRC+ (n=285) 87 (30) 145 (51) 53 (19) 198 (70) 232 (81) 






         
Subject group (n=628)         
hMLH1 (n=349) 105 (30) 171 (49) 73 (21) 244 (70) 276 (79) 






         
Subject group (n=677)         
Female (n=406) 110 (27) 217 (53) 79 (20) p=0.42 296 (73) p=0.19 327 (80) p=0.84 
Male (n=271) 86 (32) 134 (49) 51 (19)  185 (68)  220 (81)  
         
Subject group (n=405)         
Gynaecological+ (n=80) 27 (34) 38 (47) 15 (19) 53 (66) 65 (81) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 






TABLE 3.5- ALLELE FREQUNCY DISTRIBUTION OF THE rs4464148 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=678)         
CRC+ (n=286) 131 (46) 117 (41) 38 (13) 155 (54) 248 (87) 






         
Subject group (n=632)         
hMLH1 (n=353) 146 (41) 156 (44) 51 (15) 207 (59) 302 (85) 






         
Subject group (n=681)         
Female (n=409) 173 (42) 191 (47) 45 (11) 236 (58) 364 (89) 




233  (86) 
p=0.195 
         
Subject group (n=408)         
Gynaecological+ (n=80) 37 (46) 37 (46) 6 (8) 43 (54) 74 (92) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (TT) compared to combination of heterozygous and homozygous variant genotypes 
(TC+CC) 




TABLE 3.6- ALLELE FREQUNCY DISTRIBUTION OF THE rs6983267 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=667)         
CRC+ (n=282) 60 (21) 151 (54) 71 (25) 222 (79) 211 (75) 






         
Subject group (n=621)         
hMLH1 (n=344) 77 (22) 185 (54) 82 (24) 267 (78) 262 (76) 






         
Subject group (n=670)         
Female (n=403) 99 (25) 195 (48) 109 (27) 304 (75) 294 (73) 






         
Subject group (n=402)         
Gynaecological+ (n=79) 15 (19) 36 (46) 28 (35) 64 (81) 51 (65) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (TT) compared to combination of heterozygous and homozygous variant genotypes 
(TG+GG) 






TABLE 3.7- ALLELE FREQUNCY DISTRIBUTION OF THE rs7014346 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=671)         
CRC+ (n=282) 97 (34) 132 (47) 53 (19) 185 (66) 229 (81) 






         
Subject group (n=625)         
hMLH1 (n=347) 118 (34) 167 (48) 62 (18) 229 (66) 285 (82) 






         
Subject group (n=674)         
Female (n=405) 146 (36) 184 (45) 75 (19) 259 (64) 330 (81) 






         
Subject group (n=404)         
Gynaecological+ (n=79) 28 (35) 33 (42) 18 (23) 51 (65) 61 (77) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (GG) compared to combination of heterozygous and homozygous variant 
genotypes (GA+AA) 




TABLE 3.8- ALLELE FREQUNCY DISTRIBUTION OF THE rs4779584 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=666)         
CRC+ (n=280) 173 (62) 91 (32) 16 (6) 107 (38) 264 (94) 






         
Subject group (n=620)         
hMLH1 (n=342) 209 (61) 118 (35) 15 (4) p=0.18 133 (39) p=0.21 327 (96) p=0.093 
hMSH2 (n=278) 156 (56) 101 (36) 21 (8)  122 (44)  257 (92)  
         
Subject group (n=670)         
Female (n=402) 232 (58) 152 (38) 18 (4) 170 (42) 384 (96) 






         
Subject group (n=400)         
Gynaecological+ (n=80) 44 (55) 32 (40) 4 (5) 36 (45) 76 (95) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 
3p-value: Homozygous variant genotype (TT) compared to combination heterozygous and wild type genotypes 
(CT+CC) 





TABLE 3.9- ALLELE FREQUNCY DISTRIBUTION OF THE rs10795668 POLYMORPHISM IN 
THE AUSTRALIAN AND POLISH POPULATION COMBINED 
      

















Allele frequency         
Subject group (n=658)         
CRC+ (n=280) 128 (46) 121 (43) 31 (11) 152 (54) 249 (89) 






         
Subject group (n=612)         
hMLH1 (n=334) 142 (43) 152 (45) 40 (12) 192 (57) 294 (88) 






         
Subject group (n=661)         
Female (n=396) 174 (44) 173 (44) 49 (12) 223 (56) 347 (88) 






         
Subject group (n=395)         
Gynaecological+ (n=79) 33 (42) 37 (47) 9 (11) 46 (58) 70 (89) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (GG) compared to combination of heterozygous and homozygous variant 
genotypes (GA+AA) 






















Figure 3.1: Kaplan-Meier estimated by rs3802842 (SNP2) genotype in hMLH1 mutation 
carriers-Australian+Polish combined. The graph shows the effect the three genotypes (AA 
vs AC vs CC) have on age of diagnosis of CRC in the Australian and Polish HNPCC patients. 
There is a statistical significant difference between the genotypes and the age of diagnosis of 
CRC (log-rank test: p=0.0002, Breslow test: p=0.0005 and Tarone-Ware test: p=0.0003) 
 
Table 3.10: Median age of diagnosis of CRC (age at which 50% of the population is 
cancer free) in HNPCC participants for SNP rs3802842 
Genotype Subject group SNP rs3802842 1
Wild type (AA) 54 yrs (n=176)  
Heterozygote (AC) 53 yrs (n=124) 
Variant (CC) 42 yrs (n=25) 






Figure 3.2: Kaplan-Meier estimated by rs3802842 (SNP2) genotype in hMLH1 mutation 
carriers-Australian+Polish combined. The graph shows the effect of homozygous variant 
genotype (CC) compared to combination of heterozygous and wild type genotypes (AC+AA) 
have on age of age of diagnosis of CRC in Australian and Polish HNPCC patients. There is a 
statistical significant difference between the variant genotype compared to combination of 
heterozygous and wild type and the age of diagnosis of CRC (log-rank test: p=0.0001, 
Breslow test: p=0.0001 and Tarone-Ware test: p=0.0001). 
 
Table 3.11: Median age of diagnosis of CRC (age at which 50% of the population is 
cancer free) in HNPCC participants for SNP rs3802842 
Genotype Subject group SNP rs3802842 
Variant (CC) 42 yrs (n=299)  
Heterozygote (AC) + wild type (AA) 53 yrs (n=25) 







Figure 3.3: Kaplan-Meier estimated by rs3802842 (SNP2) genotype in hMLH1 mutation 
carriers-Australian only. The graph shows the effect the three genotypes (AA vs AC vs CC) 
have on age of age of diagnosis of CRC in Australian HNPCC patients. There is a statistical 
significant difference between the genotypes and the age of diagnosis of CRC (log-rank test: 
p=0.003, Breslow test: p=0.013 and Tarone-Ware test: p=0.006). 
 
Table 3.12: Median age of diagnosis of CRC (age at which 50% of the population is 
cancer free) in HNPCC participants for SNP rs3802842 
Genotype Subject group SNP rs3802842 1
Wild type (AA) 42 yrs (n=14) 
Heterozygote (AC) 50 yrs (n=64) 
Variant (CC) 54 yrs (n=85)  







Figure 3.4: Kaplan-Meier estimated by rs3802842 (SNP2) genotype in hMLH1 mutation 
carriers-Polish only. The graph shows the effect the three genotypes (AA vs AC vs CC) have 
on age of age of diagnosis of CRC in Polish HNPCC patients. There is a statistical significant 
difference between the genotypes and the age of diagnosis of CRC (log-rank test: p=0.031, 
Breslow test: p=0.034 and the Tarone-Ware tests: p=0.030). 
 
Table 3.13: Median age of diagnosis of CRC (age at which 50% of the population is 
cancer free) in HNPCC participants for SNP rs3802842 
Genotype Subject group SNP rs3802842 1
Wild type (AA) 53 yrs (n=91)  
Heterozygote (AC) 60 yrs (n=60) 

























































4 DISCUSSION  
 
The foundation for the great diversity observed in the human phenotype is based on 
genetic variation and accounts for the large variety of susceptibilities to common 
diseases [80]. Cancer is a result of the combination of germline susceptibility and 
somatic mutations, which over time accumulate resulting in an imbalance between 
cell proliferation and apoptosis. Combinations of polymorphisms in genes controlling 
cancer development are believed to be the cause of the differences seen in disease 
phenotype [81].  
 
Since the identification of the genetic basis of HNPCC in early 1990’s [1, 2] many 
studies have been undertaken to identify modifier genes that may explain at least 
some of the variation observed in disease expression in HNPCC patients [44, 48, 50, 
52, 56, 58, 82]. Unlike other genetic predispositions to colorectal cancer, such as 
Familial adenomatous polyposis (FAP), HNPCC does not present with a premalignant 
phenotype, which as such makes it difficult to predict when or if an affected person 
will present with disease.   
 
Observation of HNPCC patients who harbour germline mutation in different 
mismatch repair genes, as well as patients with the same mutation within the same 
gene do not always express the same disease patterns (age of diagnosis, severity of 
disease and appearance of extracolonic cancer) [43]. This indicates that other genes, 
modifier genes, and environmental factors are likely to influence disease expression. 
Identification of genes that influence disease expression can lead to routine use of 
molecular tests to diagnose this syndrome and establish interventions to prevent 
development of cancer [83].  
 
The current study was undertaken to identify modifier genes that might alter the 
disease expression in patients with HNPCC who are mutation positive for genes 
(hMLH1, hMSH2 and hMSH6) already associated with the disease. The candidate 
SNPs were chosen on the basis of previously reported associations between the 
particular SNPs and development of CRC. In this study, the aim was to investigate if 
the nine SNPs elected have the ability to alter disease expression in HNPCC.  
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Both inherited and genetic factors are known to contribute to the development of 
HNPCC. Recently a genome wide association study has identified a colorectal cancer 
susceptibility locus on chromosome 11q23 [72]. SNP rs3802842 is located within a 
gene rich region of chromosome 11q23 and is located close to genes encoding POU 
transcription factors [84]. The POU family of transcription factor are divided into six 
classes and the rs3802842 is close to POU class 5 [84]. The regulation of cell function 
can occur via POU factors alone, in combination with other POU proteins or together 
with other transcription factors [84]. A change in POU protein levels have been found 
in several malignancies (for example melanoma) and a study performed by Tenesa et 
al (2008), showed that locus 11q23 is associated with CRC.  
 
4.1 Age of diagnosis of CRC in hMLH1 mutation carriers  
The results from the current study are highly suggestive of a protective effect against 
CRC development in HNPCC patients carrying a mutation in hMLH1 who harbour 
the wild type or heterozygous genotype (AA+AC) for SNP rs3802842 compared to 
those carrying the variant genotype (CC), see figure 3.1. Overall, the same significant 
result was observed for all three tests performed. Our study shows that hMLH1 
mutation carriers harbouring the variant genotype (CC) develop CRC on average 11 
years earlier than hMLH1 carriers with the heterozygous or wild type genotype (AC 
or AA, see table 3.10. This indicates that the rs3802842 polymorphism is likely to act 
as a modifier of disease expression in HNPCC patients harbouring the hMLH1 
mutation. The same significant result was observed when the variant genotype was 
compared to combination of heterozygous and wild type genotypes, see figure 3.2. 
HNPCC is a dominantly inherited disease, meaning that an individual affected with 
the syndrome already has one defective allele of a gene and therefore only require a 
somatic mutation in the remaining allele to develop HNPCC related diseases. 
Individuals with the heterozygous genotype have one defective allele. So, when 
combining the wild type or variant genotype to the heterozygous genotype, we test to 
see if individuals harbouring that specific polymorphism act dominantly or recessive. 
In this case, when looking at figure 3.2 one can see that the age of diagnosis of CRC 
only differs between those individuals harbouring the variant genotype to those 
individuals harbouring either the wild type or heterozygous genotype. This means that 
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individuals harbouring SNP rs3802842 require both alleles to be defective to have an 
affect on the age of diagnosis of CRC.   
 
The same trend was also observed when the Kaplan-Meier analysis was assessed on 
the Australian and Polish population separately (see figure 3.3 and 3.4) supporting the 
result found with the combined analysis. If SNP rs3802842 is a true modifier it is 
likely to influence the likelihood of disease in all populations studied. Figure 3.3 show 
that Australian hMLH1 mutation carriers with the variant genotype (CC) develop 
CRC at a median age of 42, while hMLH1 mutation carriers with heterozygous and 
wild type genotype develop CRC at a median age of 50 and 54 respectively. The 
major difference in age of diagnosis of CRC is between hMLH1 mutation carriers 
harbouring variant genotype compared to those individuals harbouring either the wild 
type or heterozygous genotype. Moreover, this effect was also observed in the Polish 
population, see figure 2.4. The median age of diagnosis of CRC for hMLH1 mutation 
carriers with the variant genotype was 44 years as compared to 60 and 53 years for the 
AA and AC genotype respectively. Therefore, when the populations are analysed 
separately, the same result is observed for the combined analysis. However, in the 
Polish population it appears that there could be a dosage effect as the heterozygous 
genotype (AC) is an intermediate of the other two genotypes (see figure 3.4). In the 
Australian population the curve for the wild type and heterozygous genotype seem to 
follow each other more closely. This result is highly significant as it was found in two 
separate populations and when combining the number of HNPCC mismatch repair 
positive individuals is one of the largest HNPCC populations in the world. 
 
4.2 Future directions 
This is the first studiy to show that the rs3802842 polymorphism is specifically 
associated with the age of diagnosis of CRC in HNPCC patients with a hMLH1 
mutation. The previous reports regarding this SNP have been on the development of 
CRC in the general population [72]. Little is known about the function of this SNP. 
However, the SNP is located near the POU5 gene which is involved in protein 
transcription and would play a role in disease development. The polymorphisms 
involved in this study need to be functionally evaluated to determine the role of the 
polymorphism and the effect it has on the protein function. By doing this we can 
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better understand the underlying causes of why this SNP appears to act as a modifier 
of disease.   
There were differences found in the Polish and Australian population separately (See 
appendix 3 and 4), but since the differences were not found in both populations it 
appears as though the SNPs are not true modifiers of disease. They may, therefore be 
specific for a particular population. These findings obviously require further 
investigation in a larger independent cohort of MMR mutation positive HNPCC 
individuals. 
 
4.3 Limitations of the study 
Potential limitations of the study include population stratification. The most obvious 
cause of population stratification is migration where individuals from one population 
migrate into another population. However, this should not be affecting our results as 
we are searching for modifying polymorphisms affecting disease expression in 
HNPCC patients (defined group), but it cannot be ruled out.  In this study, there have 
been several examples were we have found an association in one of the populations 
studied, but not in the other.  
 
Environmental factors that are different in the two countries, could potentially affect 
the results as well as the genetic differences between two populations. Association 
studies must therefore be interpreted within the context of the genetic structure of the 
population being studied [85]. However, it has been shown that for most of the 
common disease-associated polymorphisms, ethnicity is likely to be a poor predictor 
of an individuals genotype [85].  
 
This study on SNPs has provided results that indicate that a much larger population 
should be investigated. The association of SNP rs3802842 in hMLH1 mutation 
carriers and the age of diagnosis of CRC are interesting, and require further 
investigation searching for modifying polymorphisms influencing disease expression 
has proven to be a difficult task as controversial results seems to be the rule rather 
than the exception. Nevertheless, it is believed that the elucidation of modifiers in 
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HNPCC is important as they have the potential to improve predictive genetic 







































































5 CONCLUSION  
 
The results of the current study indicated that hMLH1 mutation carriers homozygote 
variant for the rs3802842 act as a modifier of disease development. However, more 
HNPCC populations need to be studied to confirm these results. For further analysis, a 
larger study would be required with an equal proportion of Australian and Polish 
samples. Additional studies on other HNPCC populations also need to be undertaken 
to confirm the association found in this study. Only by doing so, we might be able to 
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Appendix 1: Reagents, materials and equipment used in the study 
 
Table 1: Reagents. Listed below are the concentration and supplier of the reagents used.  
Reagent Concentration  Supplier  
TaqMan® PCR Universal Master Mix 2x Applied Biosystems1  
TaqMan® SNP genotyping Assays 40x Assay-on-Demand2   
1 Applied Biosystems, Foster city, CA, USA 
2 Service offered by Applied Biosystems 
 
 
Table 2: Materials. Listed below are the materials and its suppliers. 
Materials Supplier  
96-well PCR Microplate Axygen® Scientific1
96-well Masterblock® plate Greiner Bio-One2
1 Axygen® Scientific, Union city, CA, USA 
2 Greiner Bio-One, Frickenhausen, Germany 
 
 
Table 3: Equipment. The equipment and its suppliers are listed below. 
Equipment Supplier 
ABI PRISM® 7900HT SDS Applied Biosystems1
ABI PRISM® Genetic analyser   Applied Biosystems1
Hybaid PCR Express Thermal Cycler Hybaid2
1 Applied Biosystems, Foster city, CA, USA 
2 Hybaid, Franklin, USA 
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Appendix 3: Genotype distribution in the Australian HNPCC population 
 
TABLE 1- ALLELE FREQUNCY DISTRIBUTION OF THE rs16892766 POLYMORPHISM IN 
















Allele frequency     
Subject group (n=365)     
CRC+ (n=164) 132 (80) 32 (20) 0 
CRC- (n=201) 178 (89) 23 (11) 0 
p=0.032 
   OR:1.88 CI:1.05-3.36 
Subject group (n=344)     
hMLH1 (n=180) 154 (86) 26 (14) 0 
hMSH2 (n=164) 140 (85) 24 (15) 0 
p=0.96 
     
Subject group (n=368)     
Female (n=218) 190 (87) 28 (13) 0 
Male (n=150) 123 (82) 27 (18) 0 
p=0.17 
     
Subject group (n=217)     
Gynaecological+ (n=39) 35 (90) 4 (10) 0 
Gynaecological- (n=178) 154 (87) 24 (13) 0 
p=0.793* 
     
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (AA) compared to combination of heterozygous and homozygous variant 
genotypes (AC+CC) 
3p-value: Homozygous variant genotype (CC) compared to combination of wild type and heterozygous genotypes 
(AC+AA) 
* p-value was calculated using Fisher’s exact test. 
 





























Allele frequency         
Subject group (n=359)         
CRC+ (n=162) 86 (53) 59 (36) 17 (11) 76 (47) 145 (89) 






         
Subject group (n=338)         
hMLH1 (n=174) 90 (52) 69 (40) 15 (8) 84 (48) 159 (92) 






         
Subject group (n=362)         
Female (n=213) 112 (53) 80 (37) 21 (10) 101 (47) 192 (90) 






         
Subject group (n=212)         
Gynaecological+ (n=38) 21 (55) 17 (45) 0 17 (45)   38 (100) 




  152 (88) 
p=0.017 
       OR:0.093 CI:0.005-1.56 
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (AA) compared to combination of heterozygous and homozygous variant 
genotypes (AC+CC) 

































Allele frequency         
Subject group (n=351)         
CRC+ (n=157) 113 (72) 42 (27) 2 (1) 44 (28) 155 (99) 






       OR:0.215 CI:0.047-0.984 
Subject group (n=330)         
hMLH1 (n=169) 115 (68) 49 (29) 5 (3) 54 (32) 164 (97) 






         
Subject group (n=354)         
Female (n=209) 148 (71) 56 (27) 5 (2) 61 (29) 204 (98) 






         
Subject group (n=208)         
Gynaecological+ (n=37) 25 (68) 10 (27) 2 (5) 12 (32)   35 (95) 




  168 (98) 
p=0.19 
         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 
3p-value: Homozygous variant genotype (TT) compared to combination heterozygous and wild type genotypes 
(CT+CC) 
* p-value was calculated using Fisher’s exact test. 
 





























Allele frequency         
Subject group (n=363)         
CRC+ (n=164) 57 (35) 81 (49) 26 (16) 107 (65) 138 (84) 






         
Subject group (n=342)         
hMLH1 (n=178) 53 (30) 97 (54) 28 (16) 125 (70) 150 (84) 






         
Subject group (n=366)         
Female (n=217) 57 (26) 119 (55) 41 (19) p=0.031 160 (74) p=0.010 176 (81) p=0.17 
Male (n=149) 58 (39) 71 (48) 20 (13)  91 (61)  129 (87)  
     OR:1.047 CI:0.443-0.477   
Subject group (n=216)         
Gynaecological+ (n=39) 14 (36) 17 (44) 8 (20) 25 (64)   31 (80) 




   142 (80) 
p=0.92 
         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 



































Allele frequency         
Subject group (n=367)         
CRC+ (n=165) 83 (50) 70 (43) 12 (7) 82 (50) 153 (93) 






         
Subject group (n=346)         
hMLH1 (n=182) 80 (44) 81 (44) 21 (12) 102 (56) 161 (88) 






         
Subject group (n=370)         
Female (n=220) 95 (43) 106 (48) 19 (9) 125 (57) 201 (91) 






         
Subject group (n=219)         
Gynaecological+ (n=39) 20 (51) 17 (44) 2 (5) 19 (49)    37 (95) 




   164 (91) 
p=0.747* 
         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (TT) compared to combination of heterozygous and homozygous variant genotypes 
(TC+CC) 
3p-value: Homozygous variant genotype (CC) compared to combination heterozygous and wild type genotypes 
(TC+TT) 
* p-value was calculated using Fisher’s exact test 
 
TABLE 6- ALLELE FREQUENCY DISTRIBUTION OF THE rs6983267 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=356)         
CRC+ (n=161) 31 (19) 87 (54) 43 (27) 130 (81) 118 (73) 






         
Subject group (n=335)         
hMLH1 (n=173) 37 (21) 98 (57) 38 (22) 136 (79) 135 (78) 






       OR:0.491 CI:0.304-0.795 
Subject group (n=359)         
Female (n=214) 52 (24) 103 (48) 59 (28) 162 (76) 155 (72) 






     OR:1.131 CI:0.508-2.520   
Subject group (n=213)         
Gynaecological+ (n=38) 10 (26) 16 (42) 12 (32) 28 (74)   26 (68) 




   128 (73) 
p=0.56 
         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (TT) compared to combination of heterozygous and homozygous variant genotypes 
(TG+GG) 



































Allele frequency         
Subject group (n=360)         
CRC+ (n=161) 69 (43) 73 (45) 19 (12) 92 (57) 142 (88) 






         
Subject group (n=339)         
hMLH1 (n=176) 79 (45) 80 (45) 17 (10) 97 (55) 159 (90) 






         
Subject group (n=363)         
Female (n=216) 94 (44) 93 (43) 29 (13) 122 (56) 187 (87) 
Male (n=147) 56 (38) 74 (50) 17 (12) 
p=0.39 




         
Subject group (n=215)         
Gynaecological+ (n=38) 14 (37) 18 (47) 6 (16) 24 (63)    32 (84) 




   154 (87) 
p=0.65 
         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (GG) compared to combination of heterozygous and homozygous variant 
genotypes (GA+AA) 
3p-value: Homozygous variant genotype (AA) compared to combination heterozygous and wild type genotypes 
(GA+GG) 
 





























Allele frequency         
Subject group (n=355)         
CRC+ (n=159) 107 (67) 44 (28) 8 (5) 52 (33) 151 (95) 






         
Subject group (n=334)         
hMLH1 (n=171) 111 (65) 52 (30) 8 (5) p=0.36 60 (35) p=0.17 163 (95) p=0.41 
hMSH2 (n=163) 94 (58) 58 (35) 11 (7)  69 (42)  152 (93)  
         
Subject group (n=359)         
Female (n=213) 128 (60) 77 (36) 8 (4) 85 (40) 205 (96) 






         
Subject group (n=211)         
Gynaecological+ (n=39) 21 (54) 15 (38) 3 (8) 18 (46)    36 (92) 




   167 (97) 
p=0.167* 
         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 
3p-value: Homozygous variant genotype (TT) compared to combination heterozygous and wild type genotypes 
(CT+CC) 






TABLE 9- ALLELE FREQUNCY DISTRIBUTION OF THE rs10795668 POLYMORPHISM IN 





























Allele frequency         
Subject group (n=348)         
CRC+ (n=159) 74 (47) 67 (42) 18 (11) 85 (53)     14 (89) 




  174 (92) 
p=0.28 
         
Subject group (n=327)         
hMLH1 (n=164) 74 (45) 75 (46) 15 (9) 90 (55)     149 (91) 




 152 (93) 
p=0.42 
         
Subject group (n=351)         
Female (n=208) 92 (44) 96 (46) 20 (10) 116 (56)     188 (90) 




  130 (91) 
p=0.87 
         
Subject group (n=207)         
Gynaecological+ (n=38) 16 (42) 21 (55) 1 (3) 22 (58)  37 (97) 




  150 (89) 
p=0.134* 
         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (GG) compared to combination of heterozygous and homozygous variant 
genotypes (GA+AA) 
3p-value: Homozygous variant genotype (AA) compared to combination heterozygous and wild type genotypes 
(GA+GG) 











































Figure 1: Kaplan-Meier estimated by rs16892766 (SNP1). The graph shows the effect of 
homozygous wild type genotypes (AA) compared to heterozygous genotype (AC) have on 
age of diagnosis of CRC in Australian HNPCC patients. There is a statistical significant 
difference between the genotypes and the age of diagnosis of CRC (log-rank test: p=0.004, 
Breslow test: p=0.014 and Tarone-Ware test: p=0.006). 
 
Table 10: Median age of diagnosis of CRC (age at which 50% of the population is cancer 
free) in HNPCC participants for SNP rs16892766 
Genotype Subject group SNP rs16892766 1
Wild type (AA) 52 yrs (n=297)  
Heterozygote (AC) 44 yrs (n=50) 









Figure 2: Kaplan-Meier estimated by rs16892766 (SNP1) genotype in hMLH1 mutation 
carriers. The graph shows the effect of homozygous wild type genotype (AA) compared to 
heterozygous genotype (AC) have on age of age of diagnosis of CRC in Australian HNPCC 
patients. There is a statistical significant difference between the genotypes and the age of 
diagnosis of CRC (log-rank test: p=0.001, Breslow test: p=0.001 and Tarone-Ware test: 
p=0.0008) 
 
Table 11: Median age of diagnosis of CRC (age at which 50% of the population is cancer 
free) in HNPCC participants for SNP rs16892766 
Genotype Subject group SNP rs16892766 1
Wild type  (AA) 52 yrs (n=144)  
Heterozygot (AC) 41 yrs (n=25) 








Figure 3: Kaplan-Meier estimated by rs7014346 (SNP7) genotype in hMSH2 mutation 
carriers. The graph shows the effect the three genotypes (GG vs GA vs AA) have on age of 
age of diagnosis of CRC in Australian HNPCC patients. There is a statistical significant 
difference between the genotypes for the log-rank test: p=0.031 and the age of diagnosis of 
CRC. The Breslow and the Tarone-Ware tests did not show statistical significant different 
results. 
 
Table 12: Median age of diagnosis of CRC (age at which 50% of the population is cancer 
free) in HNPCC participants for SNP rs7014346 
Genotype Subject group SNP rs7014346 1
Wild type (GG) 45 yrs (n=54)  
Heterozygote (GA) 59 yrs (n=72) 
Variant (AA) 56 yrs (n=26) 





Figure 4: Kaplan-Meier estimated by rs7014346 (SNP7) genotype in hMSH2 mutation 
carriers. The graph shows the effect of homozygous wild type genotype (GG) compared to 
combination of heterozygous and variant genotypes (GA+AA) have on age of age of 
diagnosis of CRC in Australian HNPCC patients. There is a statistical significant difference 
between the wild type genotype compared to heterozygous and variant genotypes for the log-
rank test: p=0.010 and the Tarone-Ware test: p=0.030 and the age of diagnosis of CRC. The 
Breslow test did not show a statistical significant different result. 
 
Table 13: Median age of diagnosis of CRC (age at which 50% of the population is cancer 
free) in HNPCC participants for SNP rs7014346. 
Genotype Subject group SNP rs7014346 1
Wild type (GG) 45 yrs (n=54)  
Heterozygote (GA) + variant (AA) 59 yrs (n=98) 






Figure 5: Kaplan-Meier estimated by rs4779584 (SNP8). The graph shows the effect of 
homozygous wild type genotype (CC) compared to combination of heterozygous and variant 
genotypes (CT+TT) have on age of age of diagnosis of CRC in Australian HNPCC patients. 
There is a statistical significant difference between the genotypes for the log-rank test: 
p=0.021 and the age of diagnosis of CRC. The Breslow and the Tarone-Ware tests did not 
show statistical significant different results. 
 
Table 14: Median age of diagnosis of CRC (age at which 50% of the population is cancer 
free) in HNPCC participants for SNP rs4779584 
Genotype Subject group SNP rs4779584 1
Wild type (CC) 50 yrs (n=210)  
Heterozygote (CT) + Variant (TT) 62 yrs (n=127) 






Figure 6: Kaplan-Meier estimated by rs4779584 (SNP8) genotype in hMSH2 mutation 
carriers. The graph shows the effect of homozygous wild type genotype (CC) compared to 
combination of heterozygous and variant genotypes (CT+TT) have on age of age of diagnosis 
of CRC in Australian HNPCC patients. There is a statistical significant difference between the 
wild type genotype compared to heterozygous and variant genotypes for the log-rank test: 
p=0.020 and the age of diagnosis of CRC. The Breslow and Tarone-Ware tests did not show a 
statistical significant different result. 
 
Table 15: Median age of diagnosis of CRC (age at which 50% of the population is cancer 
free) in HNPCC participants for SNP rs4779584 
Genotype Subject group SNP rs4779584 1
Wild type (CC) 49 yrs (n=85)  
Heterozygote (CT) + variant (TT) 64 yrs (n=67) 




Appendix 4: Genotype distribution in the Polish HNPCC population 
 
TABLE 1- ALLELE FREQUNCY DISTRIBUTION OF THE rs16892766 POLYMORPHISM IN 




























Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 109 (90) 12 (10) 0 12 (10) 121 (100) 






     OR:2.271 CI:1.134-4.547   
Subject group (n=286)         
hMLH1 (n=171) 145 (85) 26 (15) 0 26 (15) 171 (100) 






         
Subject group (n=311)         
Female (n=189) 161 (85) 28 (15) 0 28 (15) 189 (100) 






         
Subject group (n=189)         
Gynaecological+ (n=41) 32 (78) 9 (22) 0 9 (22) 41 (100) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (AA) compared to combination of heterozygous and homozygous variant 
genotypes (AC+CC) 
3p-value: Homozygous variant genotype (CC) compared to combination of wild type and heterozygous genotypes 
(AC+AA) 
* p-value was calculated using Fisher’s exact test 
 





























Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 70 (58) 43 (35) 8 (7) 51 (42) 113 (93) 






         
Subject group (n=286)         
hMLH1 (n=171) 96 (56) 64 (37) 11 (7) 75 (44) 160 (93) 






         
Subject group (n=311)         
Female (n=189) 106 (56) 68 (36) 15 (8) 83 (44) 174 (92) 






         
Subject group (n=189)         
Gynaecological+ (n=41) 26 (64) 10 (24) 5 (12) 15 (36) 36 (88) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (AA) compared to combination of heterozygous and homozygous variant 
genotypes (AC+CC) 
3p-value: Homozygous variant genotype (CC) compared to combination of heterozygous and wild type genotypes 
(AC+AA) 
* p-value was calculated using Fisher’s exact test. 
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Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 71 (59) 41 (34) 9 (7) 50 (41) 112 (93) 






         
Subject group (n=286)         
hMLH1 (n=171) 107 (63) 58 (34) 6 (3) 64 (37) 165 (97) 






         
Subject group (n=311)         
Female (n=189) 108 (57) 73 (39) 8 (4) 81 (43) 181 (96) 






      OR:0.536 CI:0.329-0.873  
Subject group (n=189)         
Gynaecological+ (n=41) 25 (61) 15 (37) 1 (2) 16 (39) 40 (98) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 
3p-value: Homozygous variant genotype (TT) compared to combination heterozygous and wild type genotypes 
(CT+CC) 
* p-value was calculated using Fisher’s exact test 
 





























Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 30 (25) 64 (53) 27 (22) 91 (75) 94 (78) 






         
Subject group (n=286)         
hMLH1 (n=171) 52 (31) 74 (43) 45 (26) 119 (69) 126 (74) 






         
Subject group (n=311)         
Female (n=189) 53 (28) 98 (52) 38 (20) p=0.43 136 (72) 151 (80) 




         
Subject group (n=189)         
Gynaecological+ (n=41) 13 (32) 21 (51) 7 (17) 28 (68) 34 (83) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 



































Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 48 (40) 47 (39) 26 (21) 73 (60) 95 (79) 






         
Subject group (n=286)         
hMLH1 (n=171) 66 (39) 75 (44) 30 (17) 105 (61) 141 (83) 






         
Subject group (n=311)         
Female (n=189) 78 (41) 85 (45) 26 (14) 111 (59) 163 (86) 






         
Subject group (n=189)         
Gynaecological+ (n=41) 17 (41) 20 (49) 4 (10) 24 (59) 37 (90) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (TT) compared to combination of heterozygous and homozygous variant genotypes 
(TC+CC) 
3p-value: Homozygous variant genotype (CC) compared to combination heterozygous and wild type genotypes 
(TC+TT) 
* p-value was calculated using Fisher’s exact test 
 





























Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 29 (24) 64 (53) 28 (23) 92 (76) 93 (77) 






         
Subject group (n=286)         
hMLH1 (n=171) 40 (23) 87 (51) 44 (26) 131 (77) 127 (74) 






         
Subject group (n=311)         
Female (n=189) 47 (25) 92 (49) 50 (26) 142 (75) 139 (74) 






         
Subject group (n=189)         
Gynaecological+ (n=41) 5 (12) 20 (49) 16 (39) 36 (88) 25 (61) 






     OR:0.35 CI:0.128-0954 OR:2.146 CI:1.029-4.477 
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (TT) compared to combination of heterozygous and homozygous variant genotypes 
(TG+GG) 



































Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 28 (23) 59 (49) 34 (28) 93 (77) 87 (72) 






         
Subject group (n=286)         
hMLH1 (n=171) 39 (23) 87 (51) 45 (26) 132 (77) 126 (74) 






     OR:0.576 CI:0.340-0.974   
Subject group (n=311)         
Female (n=189) 52 (28) 91 (48) 46 (24) 137 (72) 143 (76) 






         
Subject group (n=189)         
Gynaecological+ (n=41) 14 (34) 15 (37) 12 (29) 27 (66) 29 (71) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (GG) compared to combination of heterozygous and homozygous variant 
genotypes (GA+AA) 
3p-value: Homozygous variant genotype (AA) compared to combination heterozygous and wild type genotypes 
(GA+GG) 
 





























Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 66 (54) 47 (39) 8 (7) 55 (46) 113 (93) 






         
Subject group (n=286)         
hMLH1 (n=171) 98 (57) 66 (39) 7 (4) 73 (43) 164 (96) 






         
Subject group (n=311)         
Female (n=189) 104 (55) 75 (40) 10 (5) 85 (45) 179 (95) 






         
Subject group (n=189)         
Gynaecological+ (n=41) 23 (56) 17 (42) 1 (2) 18 (44) 40 (98) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (CC) compared to combination of heterozygous and homozygous variant genotypes 
(CT+TT) 
3p-value: Homozygous variant genotype (TT) compared to combination heterozygous and wild type genotypes 
(CT+CC) 






TABLE 9- ALLELE FREQUNCY DISTRIBUTION OF THE rs10795668 POLYMORPHISM IN 





























Allele frequency         
Subject group (n=311)         
CRC+ (n=121) 54 (44.5) 54 (44.5) 13 (11) 67 (55.5) 108 (89) 






         
Subject group (n=286)         
hMLH1 (n=171) 68 (40) 77 (45) 25 (15) 103 (60) 146 (85) 






         
Subject group (n=311)         
Female (n=189) 82 (44) 77 (41) 29 (15) 107 (56) 160 (85) 






       OR:2.276 CI:1.037-4.994 
Subject group (n=188)         
Gynaecological+ (n=41) 17 (41) 16 (39) 8 (20) 24 (59) 33 (80) 






         
 
CRC+ = Colorectal cancer patients, CRC- = Unaffected with colorectal cancer 
Gynaecological+ = Endometrial and ovarian cancer patients, Gynaecological- = Unaffected with Endometrial and 
Ovarian cancer 
1p-value: Comparison of the three genotype frequencies using Pearson’s Chi-square 
2 p-value: Homozygous wild type (GG) compared to combination of heterozygous and homozygous variant 
genotypes (GA+AA) 

























Figure 1: Kaplan-Meier estimated by rs16892766 (SNP1). The graph shows the effect the 
three genotypes (AA vs AC vs CC) have on age of age of diagnosis of CRC in Polish HNPCC 
patients. There is a statistical significant difference between the genotypes for the log-rank 
test: p=0.031 and the age of diagnosis of CRC. The Breslow and the Tarone-Ware tests did 
not show statistical significant different results. 
 
Table 10: Median age of diagnosis of CRC (age at which 50% of the population is cancer 
free) in HNPCC participants for SNP rs16892766 
Genotype Subject group SNP rs16892766 1
Wild type (AA) Do not reach 50% (n=252)  
Heterozygote (AC) 53 yrs (n=45) 
Variant (CC) Do not reach 50% (n=1) 





Figure 2: Kaplan-Meier estimated by rs16892766 (SNP1) genotype in hMLH1 mutation 
carriers. The graph shows the effect the three genotypes (AA vs AC vs CC) have on age of 
age of diagnosis of CRC in Polish HNPCC patients. There is a statistical significant 
difference between the genotypes for the log-rank test: p=0.023 and the age of diagnosis of 
CRC. The Breslow and the Tarone-Ware tests did not show statistical significant different 
results.  
 
Table 11: Median age of diagnosis of CRC (age at which 50% of the population is cancer 
free) in HNPCC participants for SNP rs16892766 
Genotype Subject group SNP rs16892766 1
Homozygote wild type Do not reach 50% (n=252)  
Heterozygote + Variant 53 yrs (n=46) 
1The subject group includes 298 samples 
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